RU97100179A - MONOCLONAL ANTIBODY AGAINST CD44V6 - Google Patents

MONOCLONAL ANTIBODY AGAINST CD44V6

Info

Publication number
RU97100179A
RU97100179A RU97100179/04A RU97100179A RU97100179A RU 97100179 A RU97100179 A RU 97100179A RU 97100179/04 A RU97100179/04 A RU 97100179/04A RU 97100179 A RU97100179 A RU 97100179A RU 97100179 A RU97100179 A RU 97100179A
Authority
RU
Russia
Prior art keywords
antibody
antibody molecule
molecule
molecule according
paragraphs
Prior art date
Application number
RU97100179/04A
Other languages
Russian (ru)
Other versions
RU2204606C2 (en
Inventor
Р.Адольф Гюнтер
Патцельт Эрик
Original Assignee
Берингер Ингельгейм Интернациональ ГмбХ
Форшунгсцентрум Карлсруе Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19944431297 external-priority patent/DE4431297A1/en
Application filed by Берингер Ингельгейм Интернациональ ГмбХ, Форшунгсцентрум Карлсруе Гмбх filed Critical Берингер Ингельгейм Интернациональ ГмбХ
Publication of RU97100179A publication Critical patent/RU97100179A/en
Application granted granted Critical
Publication of RU2204606C2 publication Critical patent/RU2204606C2/en

Links

Claims (17)

1. Антитело против эпитопа в аминокислотной последовательности, которая кодируется вариабельным экзоном v6 гена CD44, отличающееся тем, что оно представляет собой антитело VFF-18, которое образуется от линии клеток гибридомы, депонированной под номером DSM АСС2174.1. The antibody against the epitope in the amino acid sequence that is encoded by the variable exon v6 of the CD44 gene, characterized in that it is a VFF-18 antibody, which is formed from a hybridoma cell line deposited under DSM number ACC2174. 2. Линия клеток гибридомы, депонированная под номером DSM АСС2174. 2. The hybridoma cell line deposited under DSM number ACC2174. 3. Молекула антитела, полученная путем химической или ферментативной модификации антитела по п. 1. 3. An antibody molecule obtained by chemical or enzymatic modification of an antibody according to claim 1. 4. Молекула антитела по п. 3, отличающаяся тем, что она является фрагментом антитела по п. 1. 4. The antibody molecule according to p. 3, characterized in that it is a fragment of the antibody according to p. 1. 5. Молекула антитела по п. 4, отличающаяся тем, что она является фрагментом Fab или F(ab')2.5. The antibody molecule according to p. 4, characterized in that it is a Fab or F (ab ') 2 fragment. 6. Молекула антитела по п. 3, отличающаяся тем, что антитело связано с другой молекулой. 6. The antibody molecule according to p. 3, characterized in that the antibody is associated with another molecule. 7. Молекула антитела по п. 6, отличающаяся тем, что другая молекула является полипептидом. 7. The antibody molecule according to claim 6, characterized in that the other molecule is a polypeptide. 8. Молекула антитела по одному из пп. 3 - 5, отличающаяся тем, что она связана с радиоактивным изотопом. 8. The antibody molecule according to one of paragraphs. 3 to 5, characterized in that it is associated with a radioactive isotope. 9. Рекомбинантная молекула антитела с идиотипом антитела по п. 1. 9. The recombinant antibody molecule with the idiotype of the antibody according to claim 1. 10. Рекомбинантная молекула антитела по п. 9, отличающаяся тем, что она является химерной, приближенной к человеческой, одноцепочечной или полученной путем сцепления цепей молекулой антитела. 10. The recombinant antibody molecule according to claim 9, characterized in that it is chimeric, close to human, single-stranded or obtained by chain linking an antibody molecule. 11. Рекомбинантная молекула антитела по п. 9 или 10, отличающаяся тем, что она соединена с другой молекулой или с радиоактивным изотопом. 11. The recombinant antibody molecule according to claim 9 or 10, characterized in that it is connected to another molecule or to a radioactive isotope. 12. Молекула антитела, распознающая такой же эпитоп, как антитело по п. 1. 12. An antibody molecule that recognizes the same epitope as the antibody of claim 1. 13. Применение антитела или молекулы антитела по одному из пп. 1 или 3 - 12 для способов диагностики вне тел человека или животных. 13. The use of antibodies or antibody molecules according to one of paragraphs. 1 or 3 - 12 for diagnostic methods outside the bodies of humans or animals. 14. Применение по п. 13, отличающееся тем, что способ представляет из себя ферментный иммуносорбентный анализ или радиоиммунный анализ. 14. The use of claim 13, wherein the method is an enzyme immunosorbent assay or a radioimmune assay. 15. Применение по п. 13, отличающееся тем, что способ является иммуногистохимическим. 15. The application of claim 13, wherein the method is immunohistochemical. 16. Антитело или молекула антитела по одному из пп. 1 или 3 - 12 для фармацевтического использования. 16. The antibody or antibody molecule according to one of claims. 1 or 3 to 12 for pharmaceutical use. 17. Применение антитела или молекулы антитела по одному из пп. 1 или 3 - 11 для получения средства для диагностики in vivo. 17. The use of antibodies or antibody molecules according to one of paragraphs. 1 or 3 to 11 to obtain an in vivo diagnostic agent.
RU97100179/13A 1994-06-08 1995-06-02 Antibody vff-18 and its analogues RU2204606C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DEP4419913.9 1994-06-08
DE4419913 1994-06-08
DE19944431297 DE4431297A1 (en) 1994-09-02 1994-09-02 Antibody VFF-18 specific for epitope encoded by exon v6 of CD44
DEP4431297.0 1994-09-02

Publications (2)

Publication Number Publication Date
RU97100179A true RU97100179A (en) 1999-03-20
RU2204606C2 RU2204606C2 (en) 2003-05-20

Family

ID=25937246

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97100179/13A RU2204606C2 (en) 1994-06-08 1995-06-02 Antibody vff-18 and its analogues

Country Status (28)

Country Link
US (1) US5916561A (en)
EP (1) EP0765343B1 (en)
JP (2) JP3387929B2 (en)
KR (2) KR100379217B1 (en)
CN (1) CN1125083C (en)
AT (1) ATE197592T1 (en)
BG (1) BG64181B1 (en)
BR (1) BR9507964A (en)
CA (1) CA2192370A1 (en)
CO (1) CO4410258A1 (en)
CZ (1) CZ291274B6 (en)
DE (1) DE59508864D1 (en)
DK (1) DK0765343T3 (en)
ES (1) ES2151603T3 (en)
FI (1) FI964845A (en)
GR (1) GR3035388T3 (en)
HK (1) HK1011697A1 (en)
HU (1) HU220168B (en)
NO (1) NO317948B1 (en)
NZ (1) NZ288224A (en)
PL (1) PL190897B1 (en)
PT (1) PT765343E (en)
RO (1) RO118753B1 (en)
RU (1) RU2204606C2 (en)
SI (1) SI0765343T1 (en)
SK (1) SK282649B6 (en)
UA (1) UA58482C2 (en)
WO (1) WO1995033771A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY24389A1 (en) * 1995-12-06 2001-10-25 Karlsruhe Forschzent PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FLAT EPITHELIUM CARCINOMA
US6440733B1 (en) * 1996-02-15 2002-08-27 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel
DE19648209A1 (en) * 1996-11-21 1998-05-28 Boehringer Ingelheim Int Procedure for tumor cell depletion of CD34-positive cells
DE19708713C2 (en) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Use of preparations containing anti-CD44 antibodies for the treatment of certain tumors and for the suppression of immune reactions
WO1999064591A1 (en) * 1998-06-08 1999-12-16 Fuso Pharmaceutical Industries, Ltd. Antibody against lar phosphatase subunit
EP1097944B1 (en) * 1998-07-10 2008-10-15 Fuso Pharmaceutical Industries Ltd. Antibody against protein tyrosine phosphatase intracellular domains
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
CA2443437A1 (en) * 2001-05-18 2002-11-28 Boehringer Ingelheim International Gmbh Antibodies specific for cd44v6
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US20030103985A1 (en) * 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
WO2003018044A1 (en) * 2001-08-24 2003-03-06 Stroemblad Staffan New drug
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
AU2003272511A1 (en) * 2002-09-13 2004-04-30 Dyax Corporation Cd44-binding ligands
US20040120949A1 (en) * 2002-11-08 2004-06-24 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
EP2266593A1 (en) 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases
BR112012003686B1 (en) * 2009-08-19 2021-09-21 Merck Patent Gmbh MONOCLONAL ANTIBODIES, THEIR USE FOR DETECTION OF INTEGRIN COMPLEXES IN FFPE MATERIAL, AND POLYNUCLEOTIDE
CN102337298B (en) * 2011-08-19 2013-11-06 黄开红 Immune nano-carrier for conveying siRNA (small interfering Ribonucleic Acid) and preparation method and application thereof
ES2639855T3 (en) 2013-12-23 2017-10-30 Exchange Imaging Technologies Gmbh Nanoparticle conjugated to CD44 binding peptides
AU2018409898A1 (en) * 2018-02-22 2020-09-24 Multitude Inc. Therapeutic antibody and uses thereof
CN109593125A (en) * 2018-12-12 2019-04-09 深圳市龙华区人民医院 Antigen epitope polypeptide CD44-P1 and its application based on prostate cancer stem cells marker CD44

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672130A1 (en) * 1992-11-20 1995-09-20 Isis Innovation Limited Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
JPH08511419A (en) * 1993-06-18 1996-12-03 ヤルカネン、シルパ Composition and diagnostic method using monoclonal antibody against CD44v6
EP0767379A1 (en) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Method for the diagnosis and analysis of colon carcinoma

Similar Documents

Publication Publication Date Title
RU97100179A (en) MONOCLONAL ANTIBODY AGAINST CD44V6
US6218149B1 (en) Antibodies having modified carbohydrate content and methods of preparation and use
CA1337641C (en) Recombinant dna product and method
AU2004220156B2 (en) Monoclonal antibody and hybridoma producing the same
JPH03501440A (en) immunoreactive heterochain antibody
CA2368965A1 (en) Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders
SK154896A3 (en) Monoclonal antibody active against cd44v6 and their use
LT2005099A (en) Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof
DE60014124D1 (en) ANTIBODIES SPECIFIC TO FULLERENE
US20020197694A1 (en) Conjugates of reduced antibodies and biomolecules
Ware et al. A rat anti-mouse kappa chain specific monoclonal antibody, 187.1. 10: purification, immunochemical properties and its utility as a general second-antibody reagent
KR890702031A (en) Human Gamma, Delta T Cell Antigen Receptor Polypeptides and Hexanes
JP2831852B2 (en) Cell surface proteins expressed on human thymic cortical cells and uses thereof
US5051371A (en) Modified β2 -microglobulin
BG105294A (en) High affinity antibodies
US5175113A (en) Modified β2 -microglobulin
Leibiger et al. Glycosylation analysis of a polyreactive human monoclonal IgG antibody derived from a human-mouse heterohybridoma
KR860006989A (en) Monoclonal Antibodies Against Atrial, Sodium Diuretic Peptides Of The Human Body
JP5588585B2 (en) Antibodies against prothrombin fragment F1 + 2, their production and use
JP5123627B2 (en) Monoclonal antibody specific for heparan sulfate from dentin
Perdivara et al. Determination of primary structure and microheterogeneity of a β-amyloid plaque-specific antibody using high-performance LC–tandem mass spectrometry
Van Leuven et al. Mapping of structure-function relationships in proteins with a panel of monoclonal antibodies: A study on human α2 macroglobulin
Basta et al. Ten percent of normal B cells and plasma cells share A VH determinant (s)(J606-GAC) with a distinct subset of murine VHIII plasmacytomas.
TW201915016A (en) Monoclonal antibody or antigen-binding fragment and use of the same
CN114716547A (en) Binding protein comprising antigen binding domain and production method and application thereof